XSHG
603716
Market cap545mUSD
Oct 09, Last price
16.47CNY
1D
1.79%
1Q
14.69%
Jan 2017
-54.26%
IPO
35.22%
Name
Thalys Medical Technology Group Corp
Chart & performance
P/E
—
P/S
3.45
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.08%
Rev. gr., 5y
-12.71%
Revenues
1.08b
-40.52%
Net income
-207m
L-0.93%
CFO
-38m
L
Dividend
Jun 18, 20200.08 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Thalys Medical Technology Group Inc. is a Chinese enterprise that specializes in providing intensive medical business and operational services. The company, established in 2004, is headquartered in Wuhan, China. It previously operated under the name Thalys Medical Technology Inc. before officially adopting its current designation in September 2020.
Key people
Yan Shen
Chief Financial Officer · since 2023
Yi Lu
Deputy General Manager, Staff Elected Director · since 2025
Jian Qiu
Deputy General Manager · since 2017
Libo Wan
Deputy General Manager · since 2017
Junming Wang
Deputy General Manager · since 2017
Li Fan
Deputy General Manager, Secretary of the Board, Director · since 2024
Zheng Wang
General Manager, Director · since 2024
Wei Wen
Chairman of the Board · since 2024
Xiaoming Wen
Director · since 2015
Yicheng Wen
Director · since 2024
Independent Director · since 2024
Zhaoguo Zhang
Independent Director · since 2024
Zhen Zhang
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||